Kathmandu: Nepal is about to buy 4 million doses of the Chinese Sinopharm vaccine amid its struggle the second wave of the COVID-19 pandemic, native media reported.
However, particulars like the worth and supply date have been saved beneath wraps.
The Kathmandu Post reported that the vaccines can be purchased beneath a non-disclosure settlement, as proposed by Sinopharm, elevating concerns amongst many individuals within the Himalayan nation.
“The Cabinet has authorised the vaccine procurement unit of the Ministry of Health to buy 4 million doses of the vaccine from China,” Minister for Industry, Supplies and Commerce Rajkishwor Yadhav informed the Post.
“Other points together with worth, logistics, transportation might be regarded into by the federal government businesses involved.”
The Nepali every day newspaper reported a minister as saying that two doses of the Chinese vaccine are probably to value round USD 20.
According to a rustic`s well being ministry official, USD 20 for 2 doses would nonetheless be expensive for Nepal compared to what deal it obtained for the USD 4 AstraZeneca vaccine from the Serum Institute of India.
Last week, Bangladesh had signed a deal with China to buy the Sinopharm COVID-19 vaccine, with out disclosing the worth or amount of doses, Dhaka Tribune reported.
This comes because the disclosure of procurement worth of Sinopharm vaccine in Sri Lanka in May had sparked a row after stories emerged that Colombo had to shell out a better per-dose worth than its fellow South Asian nation Bangladesh.
According to the Daily Mirror, Sri Lanka is paying USD 15 per dose for the Sinopharm vaccine, which is USD 5 increased than what Bangladesh paid.
Bangladesh had began its inoculation drive in opposition to coronavirus with the Oxford-AstraZeneca vaccine procured from India at USD 5 per dose.
As issues stand, the Chinese vaccine is about to value Bangladesh double the AstraZeneca shot.
ALSO READ: Many killed in flash floods, landslides in Bhutan and Nepal, rescue operations underway